Annals of the New York Academy of Sciences

Cover image for Annals of the New York Academy of Sciences

May 1976

Volume 274 Myasthenia Gravis

Pages 1–677

    1. INTRODUCTION: MYASTHENIA GRAVIS IN PERSPECTIVE (pages 1–2)

      David Grob

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47670.x

  1. Part I. Structure and Function of the Neuromuscular Junction

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
  2. Part I. Structure and Function of the Neuromuscular Junction: A. Structure

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. MORPHOLOGICAL AND HISTOCHEMICAL CHANGES OF MOTOR UNITS IN MYASTHENIA (pages 6–19)

      C. Coërs and N. Telerman-Toppet

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47672.x

    2. IMMUNOPEROXIDASE LOCALIZATION OF ALPHA BUNGAROTOXIN: A NEW APPROACH TO MYASTHENIA GRAVIS (pages 20–30)

      Adam N. Bender, Steven P. Ringel, W. King Engel, Zvi Vogel and Mathew P. Daniels

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47673.x

    3. AXONAL TRANSPORT TO AND FROM THE MOTOR NERVE ENDING (pages 31–45)

      John W. Griffin, Donald L. Price, Daniel B. Drachman and W. King Engel

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47674.x

  3. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. EXPERIMENTAL ACETYLCHOLINE BLOCKADE OF THE NEUROMUSCULAR JUNCTION. EFFECTS ON END PLATE AND MUSCLE FIBER ULTRASTRUCTURE (pages 46–59)

      Stephennie S. Freeman, Andrew G. Engel and Daniel B. Drachman

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47675.x

    2. THE MOTOR END PLATE IN MYASTHENIA GRAVIS AND IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS. A QUANTITATIVE ULTRASTRUCTURAL STUDY (pages 60–79)

      Andrew G. Engel, Mitsuhiro Tsujihata, Jon M. Lindstrom and Vanda A. Lennon

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47676.x

    3. DISCUSSION (pages 80–84)

      William L. Nastuk Moderator

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47677.x

  4. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. ISOLATION AND PROPERTIES OF ACETYLCHOLINE RECEPTORS FROM ELECTROPHORUS AND TORPEDO (pages 108–115)

      Ramon Valderrama, Cheryl L. Weill, Mark McNamee and Arthur Karlin

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47679.x

    2. ACETYLCHOLINE RECEPTOR AND MYASTHENIA GRAVIS (pages 116–129)

      Bernard W. Fulpius, A. D. Zurn, D. A. Granato and R. M. Leder

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47680.x

  5. Part I. Structure and Function of the Neuromuscular Junction: D. Function

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. CHOLINERGIC RECEPTOR DESENSITIZATION (pages 130–139)

      W. L. Nastuk and C. H. Wolfson

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47681.x

    2. DISCUSSION (pages 140–142)

      William L. Nastuk Moderator

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47682.x

  6. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. CHARACTERISTICS AND MECHANISM OF NEURO-MUSCULAR BLOCK IN MYASTHENIA GRAVIS (pages 143–173)

      David Grob and Tatsuji Namba

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47683.x

    2. DIAGNOSIS OF MYASTHENIA GRAVIS BY NERVE STIMULATION (pages 174–188)

      John E. Desmedt and Samuel Borenstein

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47684.x

    3. SINGLE-MUSCLE-FIBER RECORDING OF THE JITTER PHENOMENON IN PATIENTS WITH MYASTHENIA GRAVIS AND IN MEMBERS OF THEIR FAMILIES (pages 189–202)

      Erik Stålberg, Joze V. Trontelj and Martin S. Schwartz

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47685.x

    4. THE RESULTS TO BE EXPECTED FROM ELECTRICAL TESTING IN THE DIAGNOSIS OF MYASTHENIA GRAVIS (pages 203–222)

      Coşkun Özdemir and Robert R. Young

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47686.x

    5. DISCUSSION (pages 223–225)

      Edward H. Lambert

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47687.x

  7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. MYASTHENIA GRAVIS AS A RECEPTOR DISORDER (pages 226–234)

      Daniel B. Drachman, Ing Kao, Alan Pestronk and Klaus V. Toyka

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47688.x

    2. SERUM ACETYLCHOLINE-RECEPTOR ANTIBODIES IN MYASTHENIA GRAVIS (pages 235–243)

      Richard R. Almon and Stanley H. Appel

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47689.x

    3. STUDIES ON THE ABILITY OF ACETYLCHOLINE RECEPTORS TO BIND ALPHA-BUNGAROTOXIN AFTER EXPOSURE TO MYASTHENIC SERUM (pages 244–253)

      John Keesey, Iqbal Shaikh, Frederick Wolfgram and Li-Pen Chao

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47690.x

  8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS AND MYASTHENIA GRAVIS: BIOCHEMICAL AND IMMUNOCHEMICAL ASPECTS (pages 254–274)

      Jon M. Lindstrom, Vanda A. Lennon, Marjorie E. Seybold and Senga Whittingham

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47691.x

    2. EXPERIMENTAL AUTOIMMUNE MYASTHENIA: CLINICAL, NEUROPHYSIOLOGIC, AND PHARMACOLOGIC ASPECTS (pages 275–282)

      Marjorie E. Seybold, Edward H. Lambert, Vanda A. Lennon and Jon M. Lindstrom

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47692.x

    3. EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES (pages 283–299)

      Vanda A. Lennon, Jon M. Lindstrom and Marjorie E. Seybold

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47693.x

    4. END-PLATE POTENTIALS IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS IN RATS (pages 300–318)

      Edward H. Lambert, Jon M. Lindstrom and Vanda A. Lennon

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47694.x

    5. AN IMMUNOLOGICALLY INDUCED DEFECT OF NEUROMUSCULAR TRANSMISSION IN RATS AND RABBITS (pages 319–336)

      D. B. Sanders, L. S. Schleifer, M. E. Eldefrawi, N. L. Norcross and E. E. Cobb

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47695.x

    6. EXPERIMENTAL MYASTHENIA IN RABBITS: BIOCHEMICAL, IMMUNOLOGICAL, ELECTROPHYSIOLOGICAL, AND MORPHOLOGICAL ASPECTS (pages 337–353)

      Edith Heilbronn, Christer Mattsson, Lars-Eric Thornell, Michael Sjostrom, Erik Stålberg, Per Hilton-Brown and Dan Elmqvist

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47696.x

    7. ANTIBODIES TO ACETYLCHOLINE RECEPTORS IN RABBITS: IMMUNOCHEMICAL AND ELECTROPHYSIOLOGICAL STUDIES (pages 354–376)

      Audrey S. Penn, Hai Won Chang, Robert E. Lovelace, William Niemi and Armand Miranda

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47697.x

    8. DISCUSSION (pages 377–381)

      Edward H. Lambert

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47698.x

  9. Part III. Immunologic Aspects

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. STUDIES ON THE NATURE OF AUTOIMMUNITY IN MYASTHENIA GRAVIS. EVIDENCE FOR AN IMMUNODEFICIENCY TYPE (pages 382–389)

      J. A. Simpson, P. O. Behan and Heather M. Dick

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47699.x

    2. THE ENDOCRINE THYMUS: POTENTIAL ROLE FOR THYMOSIN IN THE TREATMENT OF AUTOIMMUNE DISEASE (pages 390–401)

      Allan L. Goldstein, Gary B. Thurman, Geraldine H. Cohen and Jeffrey L. Rossio

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47700.x

  10. Part III. Immunologic Aspects: A. Lymphocytes

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. ASPECTS OF LYMPHOCYTE FUNCTION IN MYASTHENIA GRAVIS (pages 402–410)

      Robert P. Lisak, Nabih I. Abdou, Burton Zweiman, Chester Zmijewski and Audrey S. Penn

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47701.x

    2. DISTRIBUTION OF PERIPHERAL BLOOD LATEX-INGESTING CELLS, T CELLS, AND B CELLS IN PATIENTS WITH MYASTHENIA GRAVIS (pages 411–420)

      Benjamin Koziner, Kurt J. Bloch and Vincent P. Perlo

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47702.x

    3. ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY AND B- AND T-CELL ACTIVITY IN THE PERIPHERAL BLOOD OF MYASTHENIA GRAVIS PATIENTS (pages 421–433)

      Joachim R. Kalden, Ernst Lohmann, Hans H. Peter and Christa Hilger

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47703.x

    4. DISCUSSION (pages 434–439)

      W. King Engel

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47704.x

  11. Part III. Immunologic Aspects: B. HL-A Antigens

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. THE BIOLOGIC SIGNIFICANCE OF HL-A ANTIGEN MARKERS IN MYASTHENIA GRAVIS (pages 440–450)

      Dieter Fritze, Christian Herrmann Jr., Faramarz Naeim, George S. Smith, Edith Zeller and Roy L. Walford

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47705.x

    2. ON THE SIGNIFICANCE OF HL-A AND LD ANTIGENS IN MYASTHENIA GRAVIS (pages 451–460)

      Ritva Pirskanen

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47706.x

    3. MYASTHENIA GRAVIS: THE ROLE OF IMMUNOLOGICAL DEFICIENCY (pages 461–467)

      R. L. Dawkins, Caryl O'Reilly, G. Grimsley and P. J. Zilko

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47707.x

    4. HL-A ANTIGENS, AUTOANTIBODY PRODUCTION, AND ASSOCIATED DISEASES IN THYMOMA PATIENTS, WITH AND WITHOUT MYASTHENIA GRAVIS (pages 468–474)

      H. J. G. H. Oosterhuis, T. E. W. Feltkamp, A. L. van Rossum, P. M. van den Berg-Loonen and L. E. Nijenhuis

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47708.x

  12. Part III. Immunologic Aspects: C. Humoral and Cellular Factors

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. EFFECTS OF NORMAL AND MYASTHENIC SERUM FACTORS ON INNERVATED AND CHRONICALLY DENERVATED MAMMALIAN MUSCLES (pages 475–492)

      E. X. Albuquerque, F. J. Lebeda, S. H. Appel, R. Almon, F. C. Kauffman, R. F. Mayer, T. Narahashi and J. Z. Yeh

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47709.x

    2. THE ROLE OF HUMORAL AND CELLULAR IMMUNE FACTORS IN NEUROMUSCULAR BLOCK IN MYASTHENIA GRAVIS (pages 493–515)

      Tatsuji Namba, Yasunari Nakata and David Grob

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47710.x

    3. DISCUSSION (pages 516–518)

      W. King Engel

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47711.x

  13. Part IV. Management: A. Thymectomy

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. THYMIC HORMONES AS REGULATORS OF IMMUNE RESPONSES (pages 519–526)

      Otto J. Plescia, Carl Feit, Regina Skelly and Abraham White

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47712.x

    2. SUPPRESSOR LYMPHOCYTES IN MYASTHENIA GRAVIS AND EFFECT OF ADULT THYMECTOMY (pages 527–535)

      Gary Birnbaum and Peter Tsairis

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47713.x

    3. GALLIUM SCANS IN MYASTHENIA GRAVIS (pages 536–554)

      Herbert M. Swick, David F. Preston and Michael P. McQuillen

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47714.x

    4. THYMECTOMY IN MYASTHENIA GRAVIS: PATHOLOGIC, CLINICAL, AND ELECTROPHYSIOLOGIC CORRELATIONS (pages 555–573)

      Angelos E. Papatestas, Gabriel Genkins, Steven H. Horowitz and Peter Kornfeld

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47715.x

    5. DISCUSSION (pages 574–576)

      Lewis P. Rowland

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47716.x

  14. Part IV. Management: B. Corticosteroids

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. CORTICOTROPIN AND CORTICOSTEROIDS IN GENERALIZED MYASTHENIA GRAVIS: COMPARATIVE STUDIES AND ROLE IN MANAGEMENT (pages 577–595)

      Norman G. Brunner, Charles L. Berger, Tatsuji Namba and David Grob

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47717.x

    2. ALTERNATE-DAY PREDNISONE: PRELIMINARY REPORT OF A DOUBLE-BLIND CONTROLLED STUDY (pages 596–607)

      Frank M. Howard Jr., Drake D. Duane, Edward H. Lambert and Jasper R. Daube

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47718.x

    3. LONG-TERM PREDNISONE FOLLOWED BY THYMECTOMY IN MYASTHENIA GRAVIS (pages 608–622)

      J. D. Mann, T. R. Johns, J. F. Campa and W. H. Muller

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47719.x

    4. MYASTHENIA GRAVIS, CORTICOSTEROIDS, ANTICHOLINESTERASES (pages 623–630)

      W. King Engel

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47720.x

  15. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. SACCADE FATIGUE AND RESPONSE TO EDROPHONIUM FOR THE DIAGNOSIS OF MYASTHENIA GRAVIS (pages 631–641)

      R. W. Baloh and J. C. Keesey

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47721.x

    2. EDROPHONIUM INFRARED OPTOKINETIC NYSTAGMOGRAPHY IN THE DIAGNOSIS OF MYASTHENIA GRAVIS (pages 642–651)

      Robert H. Spector and Robert B. Daroff

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47722.x

    3. ORAL CORTICOSTEROIDS IN THE TREATMENT OF OCULAR MYASTHENIA GRAVIS (pages 652–658)

      Kenneth C. Fischer and Robert J. Schwartzman

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47723.x

  16. Part IV. Management: D. Immunosuppression

    1. Top of page
    2. Part I. Structure and Function of the Neuromuscular Junction
    3. Part I. Structure and Function of the Neuromuscular Junction: A. Structure
    4. Part I. Structure and Function of the Neuromuscular Junction: B. Ultrastructure
    5. Part I. Structure and Function of the Neuromuscular Junction: C. Receptors
    6. Part I. Structure and Function of the Neuromuscular Junction: D. Function
    7. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: A. Mechanism and Diagnosis
    8. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: B. Receptor Blockade
    9. Part II. Neuromuscular Transmission in Myasthenia Gravis and in Animal Models: C. Animal Models
    10. Part III. Immunologic Aspects
    11. Part III. Immunologic Aspects: A. Lymphocytes
    12. Part III. Immunologic Aspects: B. HL-A Antigens
    13. Part III. Immunologic Aspects: C. Humoral and Cellular Factors
    14. Part IV. Management: A. Thymectomy
    15. Part IV. Management: B. Corticosteroids
    16. Part IV. Management: C. Ocular Myasthenia Gravis-Diagnosis and Management
    17. Part IV. Management: D. Immunosuppression
    1. EFFECTS OF SOME IMMUNOSUPPRESSIVE PROCEDURES ON MYASTHENIA GRAVIS (pages 659–676)

      Georg Matell, Kurt Bergström, Curt Franksson, Lennart Hammarström, Ann Kari Lefvert, Erna Möller, Gösta von Reis and Edward Smith

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47724.x

    2. DISCUSSION (page 677)

      Lewis P. Rowland Moderator

      Article first published online: 16 DEC 2006 | DOI: 10.1111/j.1749-6632.1976.tb47725.x

SEARCH

SEARCH BY CITATION